Craneware plc - Director Share Purchase
Craneware plc
("Craneware", "The Craneware Group", the "Company" or the "Group")
Director Share Purchase
Following the purchase,
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
|
1. Details of the Restricted Person / person closely associated with him or her
|
|
|
a) Name |
|
|
|
|
|
2. Reason for the notification
|
|
|
a) Position / status |
CEO |
|
b) Initial notification / Amendment |
Initial notification |
|
|
|
|
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
|
a) Name |
Craneware plc |
|
b) LEI |
213800O2CTJ1YFXNXG05 |
|
|
|
|
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
|
a) Description of the financial instrument, type of instrument |
Ordinary Shares of 1p each in the capital of Craneware plc |
|
b) Identification code |
ISIN GB00B2425G68 |
|
c) Nature of the transaction |
Purchase of Ordinary Shares |
|
d) Price(s) and volume(s) |
Volume(s) 1,367 Price(s) |
|
e) Aggregated information: i. Aggregated volume ii. Price |
N/A (single transaction) - - |
|
f) Date of the transaction |
2023-01-26 |
|
g) Place of the transaction |
London Stock Exchange (XLON) |
For further information, please contact:
|
|
|
|
Craneware plc |
+44 (0)131 550 3100 |
|
|
|
|
|
|
|
|
|
|
Alma (Financial PR) |
+44 (0)20 3405 0205 |
|
|
|
|
Peel Hunt (NOMAD and Joint Broker) |
+44 (0)20 7418 8900 |
|
|
|
|
Investec Bank PLC (Joint Broker) |
+44 (0)20 7597 5970 |
|
|
|
|
Berenberg (Joint Broker) |
+44 (0)20 3207 7800 |
|
|
|
About Craneware
We at The Craneware Group of companies, including our latest additions Sentry Data Systems and Agilum Healthcare Intelligence, passionately believe we can impact healthcare profoundly by delivering the insights healthcare organisations need to also transform the business of healthcare. Our shared vision is to be the operational and financial partner for US healthcare providers.
Our combined suite of applications and industry-leading team of experts help our customers contextualise operational, financial, and clinical data, providing insights that clearly demonstrate what great looks like. These value cycle insights deliver revenue integrity and 340B compliance, as well as margin and operational intelligence - something no other single partner can provide.
Together, approximately 40% of registered US hospitals are now our customers, including more than 12,000 US hospitals, health systems and affiliated retail pharmacies and clinics. Our customers are operating with a financial impact of nearly half a trillion dollars. We have data sets from customers covering more than 150 million unique patients encounters.
Learn more at www.thecranewaregroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE